J Gynecol Oncol.  2018 May;29(3):e35. 10.3802/jgo.2018.29.e35.

Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients

• Yang B
• Xie L
• Zhang H
• Zhu Q
• Du Y
• Luo X
• Chen X

• KMID: 2409936
• DOI: http://doi.org/10.3802/jgo.2018.29.e35

Abstract

OBJECTIVE
Our previous study showed that insulin resistance (IR) was related to endometrial hyperplasia as well as endometrial cancer. But the exact impact of IR on fertility-sparing treatment in endometrial hyperplasic disease is unclear. This study investigated how IR affects fertility-sparing treatment in endometrial atypical hyperplasia (EAH) patients.
METHODS
The 151 EAH patients received fertility-sparing treatment were retrospectively investigated. All patients received high-dose progestin combined with hysteroscopy. Therapeutic effects were evaluated by hysteroscopy every 3 months during the treatment.
RESULTS
The median age was 33.0 years old (range, 21-54 years old). Sixty-one patients (40.4%) were insulin resistant. Three patients were excluded from the analysis because they chose hysterectomy within 3 months after initiation of progestin treatment. The 141 out of 148 (95.3%) patients achieved complete response (CR). No difference was found in cumulative CR rate between those with or without IR (90.2% vs. 95.6%, p=0.320). IR significantly affected therapeutic duration to achieve CR (8.1±0.5 months with IR vs. 6.1±0.4 months without IR, p=0.004). Overweight (body mass index [BMI]≥25 kg/m2) was associated with higher risk of treatment failure (odds ratio=5.61; 95% confidence interval=1.11-28.35; p=0.040) and longer therapeutic duration to achieve CR (7.6±0.5 months vs. 6.3±0.4 months, p=0.019). EAH patients with both IR and overweight (IR+BMI+) had the longest therapeutic time compared with other patients (8.8±0.6 months vs. 5.6±0.7, 6.3±0.4, and 6.4±0.8 months for IR−BMI+, IR−BMI−, and IR+BMI−, respectively, p=0.006).
CONCLUSION
IR and overweight were associated with longer therapeutic duration in EAH patients receiving progestin-based fertility-sparing treatment.

Keyword

Endometrial Hyperplasia; Conservative Treatment; Overweight; Insulin Resistance

MeSH Terms

Endometrial Hyperplasia
Endometrial Neoplasms
Female
Humans
Hyperplasia*
Hysterectomy
Hysteroscopy
Insulin Resistance*
Insulin*
Overweight*
Retrospective Studies
Therapeutic Uses
Treatment Failure
Insulin
Therapeutic Uses